News
Novo Nordisk's early lead in weight-loss drugs fades as Eli Lilly surges ahead with more effective therapies and faster ...
The agreement unites two brands that are popular with Gen Z and helps the buyer diversify its supply chain outside of China. Pipeline operator Williams will seek to build two natural-gas supply lines ...
2h
Bangkok Post on MSNThammasat, Novo Nordisk Unite for Holistic Diabetes, Obesity CareThammasat University Hospital, in collaboration with Novo Nordisk Pharma (Thailand) Ltd. ('Novo Nordisk'), announced a collaboration titled 'Partnership Project for the Transition into the Fourth ...
Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...
European stocks were mostly higher after a court stuck down Trump's sweeping tariff agenda. The Court of International Trade on Wednesday ruled that Trump wrongfully invoked an emergency law to impose ...
Seven pharmaceutical giants with a presence in New Jersey have announced billions in expansions. The timing is no surprise, health care analysts say.
Explore more
Novo Nordisk’s weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly’s Zepbound, and now the ...
LONG ISLAND - Michael, a 48-year-old from Suffolk County, is suing Ozempic's manufacturer for loss of vision. Michael, who opted out of sharing his surname, says that the loss of sight began after his ...
Novo Nordisk warned the US government not to impose pharma-specific tariffs, but instead to tax illegal importers of ...
Glenmark Pharmaceuticals seeks licensing deal for ISB 2001 drug candidate, plans growth with semaglutide in India.
The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...
The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results